semaglutide bad for kidneys in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Not all GLP-1 receptor agonists

Risk factors include female gender, increased age, cardiovascular disease, diabetes mellitus, constipation, irritable bowel syndrome, thrombophilia, history of abdominal aortic aneurysm repair, constipation-inducing drugs, immunomodulators, and other illicit drug use [1,2,3]

Some even report feeling energized enough to have more productive afternoons following their injection.

What actually works right now: the unsexy answer If youre on a GLP-1 drug today or considering one and youre worried about muscle loss, heres the reality: the myostatin inhibitors arent available yet, the trials are early-stage, and even the most promising candidate (apitegromab) hasnt shown functional strength benefits

Berberine offers promising metabolic benefits, including improved glucose control and lipid profiles, supported by preliminary clinical and mechanistic studies

Analyses included the effects of various dosing conditions (such as fasting time and water volume), demographic covariates and variability in exposure following single and multiple oral administration

"I was to see my GP because of my gut problems.." Have you been referred to a gastro enterologist